Starpharma Holdings Ltd has released a press release.
$3.7M R&D Tax Incentive Received
Filed with ASX ·
6ix hasn’t read this filing yet.
Starpharma Holdings Limited on 6ix
Earlier from Starpharma
- FY25 Key Financial Results and Annual Report
- 2025 Appendix 4E Preliminary Financial Report
- SPL receives positive FDA feedback on DEP SN38 for PROC
- AGM Chair's address and CEO's presentation
- SPL7013 Nasal Spray Australia Update
Later from Starpharma
- Starpharma Announces License Agreement with Genentech
- Presentation to Accompany License Agreement with Genentech
- Starpharma Announces a Collaboration and License Agreement with Genentech
- SPL: Research & Option Agreement with Radiopharm Theranostics
- Upfront payment of USD $5.5 million received from Genentech
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma